Gyre Therapeutics' stock is volatile - I'm upholding my "Hold" rating due to uncertain long-term prospects and potential dilution from future funding needs. The company's products include Etuary ...

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that ...

The stock price didn't jump after Gyre Therapeutics, Inc. (NASDAQ:GYRE) posted decent earnings last week. We did some digging and believe investors may be worried about some underlying factors in ...

Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last posted its quarterly earnings data on Monday, March 17th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of ...

Gyre plans to submit an IND application in 2026. For the full year 2025, the Company expects to generate revenues of $118 to $128 million, representing growth of 11.3% to 20.8% over 2024 revenue ...

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report)’s stock price gapped down prior to trading on Tuesday following a weaker than expected earnings announcement. The stock had previously ...